Temporary Extension of Eligibility for the NIDDK K01 Mentored Research Scientist Development Award During the COVID-19 Pandemic
Notice Number:
NOT-DK-20-054

Key Dates

Release Date:

November 17, 2020

Related Announcements

PAR-18-418 - NIDDK Mentored Research Scientist Development Award (K01-Clinical Trials Required)

PAR-18-419 - NIDDK Mentored Research Scientist Development Award (K01 No Independent Clinical Trials)

PA-20-190 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)

PA-20-176 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

Under normal circumstances, individuals applying to the NIH Mentored Research Scientist Development Award (K01) with a project within the mission interests of the NIDDK must have no more than 7 years of post-doctoral research experience. The purpose of this notice is to inform the extramural community that due to disruptions caused by the COVID-19 pandemic, the NIDDK will be providing up to a two-receipt cycle extension (roughly eight additional months) of eligibility for prospective applicants meeting the requirements for submission of a K01 application from the time period covered by the June/July 2020 due dates through the February/March 2021 due dates.

Implementation

The two-receipt cycle extension in eligibility under this Notice applies only to applicants for a K01 award under one of the following Funding Opportunity Announcements: PAR-18-419: NIDDK Mentored Research Scientist Development Award (K01-No Independent Clinical Trials), PAR-18-418: NIDDK Mentored Research Scientist Development Award (K01-Clinical Trials Required), PA-20-176: Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required), and PA-20-190: Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed).

For eligible applicants submitting new or resubmission applications, the two-receipt cycle extension will be automatically accepted by the NIH; no additional documentation is required.

To aid potential applicants in determining whether they are eligible for the extension, the following examples are provided:

Example 1: For individuals whose eligibility ended with the June/July 12, 2020 due dates, the temporary extension would allow them to apply for the K99/R00 in October/November 2020 or February/March 2021.

Example 2: For individuals whose eligibility ended with October/November 12, 2020 due dates, the temporary extension would allow them to apply in February/March 2021 or June/July 2021.

Example 3: For individuals whose eligibility would normally end with February/March 12, 2021 due dates, the temporary extension would allow them to apply in June/July 2021 or October/November 2021.

This policy may be subject to future updates.

Inquiries

Please direct all inquiries to:

Tracy L. Rankin, Ph.D., M.P.H.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: (301) 594-4748
Email: rankint@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices